MX2022002360A - Anticuerpos de anti-il31 para uso veterinario. - Google Patents
Anticuerpos de anti-il31 para uso veterinario.Info
- Publication number
- MX2022002360A MX2022002360A MX2022002360A MX2022002360A MX2022002360A MX 2022002360 A MX2022002360 A MX 2022002360A MX 2022002360 A MX2022002360 A MX 2022002360A MX 2022002360 A MX2022002360 A MX 2022002360A MX 2022002360 A MX2022002360 A MX 2022002360A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- feline
- canine
- veterinary use
- enhanced binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G01N33/6869—Interleukin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/54—Interleukins [IL]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962893799P | 2019-08-29 | 2019-08-29 | |
| US201962894526P | 2019-08-30 | 2019-08-30 | |
| PCT/US2020/048618 WO2021041972A1 (en) | 2019-08-29 | 2020-08-28 | Anti-il31 antibodies for veterinary use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022002360A true MX2022002360A (es) | 2022-04-06 |
Family
ID=74686094
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022002360A MX2022002360A (es) | 2019-08-29 | 2020-08-28 | Anticuerpos de anti-il31 para uso veterinario. |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220324960A1 (https=) |
| EP (1) | EP4021499A4 (https=) |
| JP (1) | JP7671275B2 (https=) |
| KR (1) | KR20220071191A (https=) |
| CN (1) | CN114555121A (https=) |
| AU (1) | AU2020336210A1 (https=) |
| BR (1) | BR112022002771A2 (https=) |
| CA (1) | CA3147809A1 (https=) |
| MX (1) | MX2022002360A (https=) |
| WO (1) | WO2021041972A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102460040B1 (ko) | 2016-04-27 | 2022-11-01 | 애브비 인코포레이티드 | 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 |
| WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| CN114989299B (zh) * | 2022-06-21 | 2023-05-26 | 北京索莱宝科技有限公司 | 一种单克隆抗体的组合物及其应用、检测人白细胞介素1β的试剂、试剂盒和方法 |
| CN117186220A (zh) * | 2023-07-20 | 2023-12-08 | 北京伟杰信生物科技有限公司 | 可结合白介素31的抗体或其抗原结合片段及其制备方法和应用 |
| CN120865402A (zh) * | 2023-11-27 | 2025-10-31 | 宁波贝安生物科技有限公司 | 抗il-31的抗体及其用途 |
| CN121108334A (zh) * | 2024-06-11 | 2025-12-12 | 优迈生物科技(连云港)有限公司 | 抗犬il-31的抗体及其应用 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE335072T1 (de) * | 1993-05-28 | 2006-08-15 | Scripps Research Inst | Methoden für inhibition der cd14-abhängigen zellaktivierung |
| US7084257B2 (en) * | 2001-10-05 | 2006-08-01 | Amgen Inc. | Fully human antibody Fab fragments with human interferon-gamma neutralizing activity |
| EP1485126A4 (en) * | 2001-12-21 | 2007-03-21 | Idexx Lab Inc | DOG IMMUNOGLOBULIN VARIABLE DOMAINS, DOG ANTIBODIES, AND METHOD FOR THEIR PRODUCTION AND USE |
| CN102321174B (zh) * | 2005-05-06 | 2013-10-16 | 津莫吉尼蒂克斯公司 | Il-31单克隆抗体及使用方法 |
| DK2594586T3 (en) * | 2006-09-01 | 2014-11-17 | Zymogenetics Inc | Monoclonal il-31 antibodies and methods of use thereof |
| GB2504887B (en) * | 2011-05-06 | 2016-02-03 | Nvip Pty Ltd | Anti-Nerve growth factor antibodies and methods of preparing and using the same |
| US8790651B2 (en) * | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
| HK1201281A1 (en) * | 2011-10-13 | 2015-08-28 | Nexvet Australia Pty Ltd | Canine/feline cd20 binding epitope and compositions for binding thereto |
| CA2886161A1 (en) * | 2012-09-29 | 2014-04-03 | The Trustees Of The University Of Pennsylvania | Veterinary composition and methods for non-surgical neutering and castration |
| US9499621B2 (en) * | 2013-04-08 | 2016-11-22 | Cytodyn, Inc. | Felinized antibodies and methods of treating retroviral infections in felines |
| CN103965357B (zh) * | 2013-12-31 | 2016-08-17 | 嘉和生物药业有限公司 | 一种抗人rankl抗体 |
| KR20170134748A (ko) * | 2015-04-14 | 2017-12-06 | 추가이 세이야쿠 가부시키가이샤 | Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물 |
| CN109789201B (zh) * | 2016-04-15 | 2023-06-16 | 伊穆奈克斯特股份有限公司 | 抗人vista抗体及其用途 |
| WO2017192589A1 (en) * | 2016-05-02 | 2017-11-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Neutralizing antibodies to influenza ha and their use and identification |
| WO2018156180A1 (en) * | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
| MX2020006105A (es) * | 2017-12-11 | 2020-11-09 | Ubi Ip Holdings | Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica. |
| WO2020056393A1 (en) * | 2018-09-14 | 2020-03-19 | Kindred Biosciences, Inc. | Anti-il4 receptor antibodies for veterinary use |
-
2020
- 2020-08-28 CA CA3147809A patent/CA3147809A1/en active Pending
- 2020-08-28 BR BR112022002771A patent/BR112022002771A2/pt unknown
- 2020-08-28 KR KR1020227009547A patent/KR20220071191A/ko not_active Ceased
- 2020-08-28 EP EP20858503.4A patent/EP4021499A4/en active Pending
- 2020-08-28 AU AU2020336210A patent/AU2020336210A1/en active Pending
- 2020-08-28 JP JP2022511238A patent/JP7671275B2/ja active Active
- 2020-08-28 MX MX2022002360A patent/MX2022002360A/es unknown
- 2020-08-28 WO PCT/US2020/048618 patent/WO2021041972A1/en not_active Ceased
- 2020-08-28 US US17/638,372 patent/US20220324960A1/en active Pending
- 2020-08-28 CN CN202080073011.6A patent/CN114555121A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4021499A4 (en) | 2024-08-07 |
| EP4021499A1 (en) | 2022-07-06 |
| BR112022002771A2 (pt) | 2022-08-09 |
| US20220324960A1 (en) | 2022-10-13 |
| AU2020336210A1 (en) | 2022-03-03 |
| JP7671275B2 (ja) | 2025-05-01 |
| JP2022545259A (ja) | 2022-10-26 |
| WO2021041972A1 (en) | 2021-03-04 |
| CN114555121A (zh) | 2022-05-27 |
| CA3147809A1 (en) | 2021-03-04 |
| KR20220071191A (ko) | 2022-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022002360A (es) | Anticuerpos de anti-il31 para uso veterinario. | |
| MX2024012304A (es) | Anticuerpos anti-il31 para uso veterinario | |
| MX2021002971A (es) | Anticuerpos del receptor anti-interleucina 4 para uso veterinario. | |
| CY1123791T1 (el) | Μονοκλωνικο αντισωμα ιντερλευκινης-31 | |
| MX2022013147A (es) | Anticuerpos anti-interleucina 31 de acción prolongada para uso veterinario. | |
| MX2022011335A (es) | Anticuerpos del receptor anti-interleucina 4 para uso veterinario. | |
| CY1124730T1 (el) | Αντισωματα εναντι pd-1 και χρησεις αυτων | |
| EA202091976A1 (ru) | Вариабельные домены антител, нацеленные на cd33, и их применение | |
| AU2018254542A1 (en) | IL4/IL13 receptor molecule for veterinary use | |
| CO2021013279A2 (es) | Anticuerpos de cadena pesada que se unen al psma | |
| PE20150023A1 (es) | Proteinas de union a antigeno st2 | |
| UY37083A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso | |
| ECSP18013690A (es) | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) | |
| EA201390146A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| MX2022013149A (es) | Moléculas receptoras de interleucina 4/interleucina 13 para uso veterinario. | |
| BR112012022342A2 (pt) | anticorpos monoclonais dirigidos a cd52 | |
| PH12014501927A1 (en) | Antibodies to matrix metalloproteinase 9 | |
| MX2020010837A (es) | Ratones que expresan un repertorio limitado de cadena ligera de inmunoglobulina. | |
| EA201600252A1 (ru) | Модифицированные антитела к рецепторам антиэпидермального фактора роста и способы их использования | |
| PH12014501931A1 (en) | Antibodies to matrix metalloproteinase 9 | |
| BR112012022338A2 (pt) | anticorpos monoclonais direcionados a cd20 | |
| MX2022001104A (es) | Anticuerpos de parvovirus para uso veterinario. | |
| JP2013520990A5 (https=) | ||
| MX2021010877A (es) | Moleculas de union a cumulo de diferenciacion 3 (cd3). | |
| BR112023020574A2 (pt) | Anticorpos biespecíficos alvejados a nkp46 e cd38 e métodos de uso dos mesmos |